Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of RX108 in recurrent or metastatic head and neck squamous cell carcinoma
CTR20200531Phase 2Active
- Sponsor
- Suzhou Runxin Biotechnology
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of RX108 in head and neck squamous cell carcinoma (HNSCC), sponsored by Suzhou Runxin Biotechnology. Started Jul 2020; status: active.
02
Drugs
RX108
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on CTR20200531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200531.